Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
about
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humansAn animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamusRole of bed nucleus of the stria terminalis and amygdala AMPA receptors in the development and expression of context conditioning and sensitization of startle by prior shock.Advances in the treatment of anxiety: targeting glutamate.Contextual control over expression of fear is affected by cortisolAcute pharmacological modulation of mGluR8 reduces measures of anxiety.Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramineThe role of glutamate in anxiety and related disorders.Role of functional magnetic resonance imaging in drug discovery.Structure and ligand recognition of class C GPCRsIn search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.Pharmacotherapies in the management of obsessive-compulsive disorder.Metabotropic glutamate receptor blockade in nucleus accumbens shell shifts affective valence towards fear and disgust.Post-traumatic stress disorder: emerging concepts of pharmacotherapy.Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.Cerebral 5-HT2A receptor binding, but not mGluR2, is increased in tryptophan hydroxylase 2 decrease-of-function miceGABA and glutamate systems as therapeutic targets in depression and mood disorders.Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators.Emotional learning and glutamate: translational perspectivesOpportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings.Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsInvolvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation.Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys.Contextual conditioning in rats as an animal model for generalized anxiety disorder.Emerging drugs for panic disorder.Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators.Glutamate-based anxiolytic ligands in clinical trials.Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.Investigational drugs under development for the treatment of PTSD.The individual and combined effects of phenmetrazine and mgluR2/3 agonist LY379268 on the motivation to self-administer cocaine.Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.Metabotropic glutamate receptors: potential drug targets for psychiatric disorders.The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-/-), GRM3(-/-) and GRM2/3(-/-) knockout mice.[Glutamatergic neurotransmission as molecular target in anxiety].Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis.Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.Bidirectional regulation of synaptic plasticity in the basolateral amygdala induced by the D1-like family of dopamine receptors and group II metabotropic glutamate receptors.Differential changes of group II and group III mGluR function in central amygdala neurons in a model of arthritic pain.
P2860
Q24654140-39BA9C8D-8C4A-4763-B1D8-64385843003DQ27008085-2FC0CC28-A517-429A-8B73-7FFD6AF1B520Q30399742-F8EDD5B2-0195-4B8B-9413-97E4159D6DF7Q30457479-92D79A7E-7450-4559-B8A2-A066FEC96994Q30462364-365FCA52-E38A-4AA7-9158-5C6E6C8CAC29Q30473719-7B83457C-F571-475B-A6BA-600067DD6657Q30488931-057757D2-091B-4868-9F60-C771D7A10759Q31029023-2547878D-2A0E-459F-80FB-C0AA56CF0583Q31109439-59360F8F-0D5C-41AF-892B-40A4623E3B7EQ33828724-7257C19A-C4C9-47D6-8B4D-59B235466127Q34292427-0D3AE967-784E-444A-9D84-50311D737CDBQ34547177-3ACC53DE-5B3A-4A42-A537-FB3A1B0518A3Q34574309-E198D2A7-2CAF-4C97-B24E-C755F6A79C6DQ34981801-2A2A2CC5-A268-46DF-B0EE-526BF7FD8CDCQ34992163-A93F5791-4213-4A1F-9822-8423EC69CC48Q35068582-7ADC9B71-5BC5-4773-8FDD-72917EC4B497Q36066308-E9E38524-C538-4DDB-AA0F-F69BE0EAC56DQ36263703-89DE3C67-EC16-46FA-8D12-B762D4C34E15Q36363614-31E8F878-326C-4042-85D1-61A0B28948C3Q37064021-E46C7801-1113-4E40-B856-02CED6E6AD75Q37169626-1EE3AAD6-24A5-463F-B6E2-7F7DE688DD8BQ37183072-BE2507DA-D09A-4670-B489-0BDF00C3E7C8Q37315470-7F9F20AB-2A0D-468B-A6D5-2A41757A6CEFQ37360436-98D70B26-4135-4794-8F05-D3FDC15A434FQ37366802-488A2516-2255-4908-8E14-2F109AE770F8Q37837718-81C89C3B-EF6F-40B2-8F37-1F6CCC0E0AC1Q37945699-76457409-E9FB-4F1D-AAF6-4798954122F8Q38031831-F2BE2E32-0717-485F-B36D-70924F8C9754Q38110306-E8425947-D386-492D-87BF-C42BB4796B19Q38292149-CCA62B0C-23A6-45D8-9381-23C2AF227556Q38378939-EA4C2E59-3ED0-410B-A4E2-7F2A86D3B3E8Q39618347-3123CDBC-7F95-41E8-B894-CE5445F532DFQ40410370-D7E68772-288D-40E3-BE5D-78028A83F676Q41157725-050C3205-E72D-4FB3-A180-C1EFA43E1FB3Q43058779-0F020E3D-136B-4F93-8848-D5F6C53DB4FFQ44773109-DB280E1E-62CC-424E-90C4-A3991D6C7418Q46423982-B224FD68-8A2C-4FEC-90F7-86A792727D81Q48106927-398943A1-AFD0-4371-A9A2-4F52DD356999Q48236589-04090048-1820-4BEE-B548-CF090116E3E1Q48506273-F1ACB7C9-298F-4AC6-8223-7518D609367B
P2860
Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@ast
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@en
Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist
@nl
type
label
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@ast
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@en
Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist
@nl
prefLabel
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@ast
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@en
Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist
@nl
P2093
P1433
P1476
Anxiolytic effects of a novel ...... ed startle paradigm in humans.
@en
P2093
Charles A Morgan
Christian Grillon
Jeremy Cordova
Louise R Levine
P2888
P304
P356
10.1007/S00213-003-1444-8
P577
2003-04-23T00:00:00Z
P6179
1039854221